Retour au texte principal

Investor Relations

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

Nitto always aims for fair disclosure to ensure that our investors can properly evaluate our corporate value.

What's New RSS

The Nitto website is currently under system maintenance. Please try again later.
2016/Nov/11 Bristol-Myers Squibb signe un accord de licence mondial avec Nitto Denko pour sa thérapie de siARN ciblé pour le traitement de la stéatohépatite non-alcoolique (SHNA) avancée et de la cirrhose causée par la SHNA
2016/Nov/02 Démarrage de la phase I des tests cliniques des comprimés sublinguaux du vaccin contre la grippe saisonnière HA
2016/Oct/31 Notice Regarding Dividends from Surplus and Revision of Dividend Forecast
Notice
 
Please be advised that except for current and past facts, the performance outlooks and business strategies presented in this Website are based on projections and judgments by NITTO DENKO management, and may differ from the actual performance.

Moreover, as it is not the intention of this Website to solicit any investments in NITTO DENKO stocks, visitors intending to do so are advised to make their investment decisions solely based on their own judgment.

Retour en haut de la page